Burning Rock Biotech (NASDAQ:BNR) Announces Quarterly Earnings Results

Burning Rock Biotech (NASDAQ:BNR) announced its quarterly earnings results on Tuesday. The company reported ($1.08) earnings per share for the quarter, Zacks reports. Burning Rock Biotech had a negative net margin of 83.50% and a negative return on equity of 60.68%.

Burning Rock Biotech Price Performance

BNR opened at $5.67 on Tuesday. The stock has a market cap of $58.03 million, a P/E ratio of -1.89 and a beta of 0.55. The firm has a fifty day moving average price of $6.32 and a 200 day moving average price of $5.28. Burning Rock Biotech has a 1 year low of $2.62 and a 1 year high of $8.99.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.